Capsaicin for Cerebral Perfusion Augmentation.

Stroke Clinical Trial

Official title:

Dose-Escalation and Safety of Capsaicin for Cerebral Perfusion Augmentation. A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04545892
• Other study ID #: Cap1
• Status: Completed
• Phase: Phase 1
• Start date: December 1, 2019
• Est. completion date: July 31, 2020

Study information

• Verified date: September 2020
• Source: Unidad de Medicina de Alta Especialidad, Torre Medica CMQ
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine the safety and effect of crescent doses of capsaicin upon serial transcranial Doppler (TCD) markers of cerebral blood flow (CBF). Methods We performed serial TCD testing in 30 healthy volunteers divided into five equal groups. Capsaicin doses ranged from 33 to 165 μMol. We recorded peak systolic and end-diastolic velocities in the middle cerebral artery (MCA), arterial pressure, and perceived pungency (PP) in five minutes intervals up to 20 minutes. We then calculated the mean velocity (MV), the pulsatility index (PI), and the CBF index.

Description:

Subjects We studied 30 healthy volunteers. Call for volunteer flyers were distributed among undergraduate students of the local faculty of medicine. Interested individuals made an appointment to get more information. Those willing to participate signed the informed consent form (ICF) and received instructions to refrain from eating or drinking at least one h before the TCD measurements, and not to eat spicy food for one day before testing. The volunteers were normotensive, not smoking, not taking any medication, and did not have any oral cavity disorder. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate. Therefore, half of the participants in each dose group received stimulation on either left or right side of the palate. Chemical stimuli From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water. The rehydrated filter paper was applied and remained stationary on the subject's hemi palate's posterior surface during TCD measurements. Participants were instructed not to swallow and to avoid touching the paper filter with their tongue for the 20 minutes of the experiment.

TCD testing With a TCD device (Philips Sonos 7500®), we recorded peak systolic velocity (PSV) and end-diastolic velocity (EDV) in the middle cerebral artery (MCA) through the temporal window of the stimulated side. First, we obtained a basal recording and an immediate recording after stimulation, followed by serial recordings every five minutes and up to 20 minutes. At each time point, we also registered: systolic pressure (SP), diastolic pressure (DP), and perceived pungency (PP) on a visual analog scale. TCD markers of cerebral blood flow From the initial measurements we calculated: Mean velocity (MV) = EDV + [(PSVEDV) / 3], pulsatility index (PI) = PSV - EDV / MV, mean arterial pressure (MAP) = ((2 * DP) + SP) / 3 and, the CBF index (CBFi).

, CBFi = (MAP * 10) / 1.47^PI. Statistical analysis Shapiro Wilkins W-Test were performed. Because the data did not follow a normal distribution, the results of the continuous variables are described as median and ranges. The categorical variables are described as tables of absolute and relative frequencies, and the comparisons between the groups of subjects (according to the dose of capsaicin) were carried out with chi-square tests. To compare the variables studied between the groups of subjects (according to the different doses of capsaicin), Mann-Whitney U-Test tests were used. In order to make comparisons of the baseline state with the changes observed in the study variables over time, various Wilcoxon signed-rank tests were performed.The relationship between pungency ratings and MV response was evaluated by Spearman's rho test. The level of statistical significance was set at 0.05.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Those willing to participate with signed the informed consent form (ICF)

• No diagnosis of any chronic or acute disorder

Exclusion Criteria:

• Eating or drinking at least one h before the measurements

• Eating spicy food for one day before testing.

• Hypertension

• Smoking

• Any disorder of the oral cavity

Related Conditions & MeSH terms

• Stroke

Intervention

Drug:
• Capsaicin
One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water

Locations

Country	Name	City	State
Mexico	Unidad de Medicina de Alta Especialidad en Torre Médica CMQ	Aguascalientes	Ags.

Sponsors (3)

Lead Sponsor	Collaborator
Juan Manuel Marquez Romero	Centenario Hospital Miguel Hidalgo, Universidad de Guanajuato

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean velocity	The Mean velocity in the Middle Cerebral Artery	20 minutes
Primary	Pulsatility Index	A calculated flow parameter in ultrasound, derived from the maximum, minimum, and mean Doppler frequency shifts during a defined cardiac cycle.	20 minutes
Secondary	Mean arterial pressure (MAP)	The average arterial pressure throughout one cardiac cycle, systole, and diastole.	20 minutes
Secondary	Cerebral Blood Flow index	The result of the following formula: CBFi = (MAP * 10) / 1.47^Pulsatility Index.	20 minutes